China Infrastructure Construction Corp. (OTCPK: CHNC) Explores STEM CELL Opportunity

HOUSTON, TX, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- China Infrastructure Construction Corp. (OTC:PK: CHNC) -hdh.com announces it has commenced due diligence of a new business opportunity in STEM CELL Medicine. 

“Hippocrates Direct Healthcare Inc, a wholly owned subsidiary of CHNC, maintains a medical office and also does clinical research for pharmaceutical companies. Hippocrates is now moving its membership-based model into a unique surgical subspecialty of medicine. As a Houston-based medical office we feel we will be well positioned to bring STEM CELL medicine to Houston and continue our march towards bringing our patients quality and value in all aspects of medicine,” said President & CEO Elizabeth Hernandez.

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

Hippocrates Direct Healthcare™ and the Hippocrates Direct Healthcare™ logo are all trademarks or registered trademarks of Hippocrates Direct Healthcare™, Inc.